ECSP22032209A - Combinación farmacéutica de inhibidores de prmt5 - Google Patents
Combinación farmacéutica de inhibidores de prmt5Info
- Publication number
- ECSP22032209A ECSP22032209A ECSENADI202232209A ECDI202232209A ECSP22032209A EC SP22032209 A ECSP22032209 A EC SP22032209A EC SENADI202232209 A ECSENADI202232209 A EC SENADI202232209A EC DI202232209 A ECDI202232209 A EC DI202232209A EC SP22032209 A ECSP22032209 A EC SP22032209A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitor
- pharmaceutical combination
- kras
- modulator
- prmt5
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación se refiere a combinaciones farmacéuticas para tratar y/o prevenir el cáncer y métodos y usos de las mismas. Más particularmente, se proporcionan una combinación farmacéutica que comprende un inhibidor de PRMT5 y un modulador de la actividad celular seleccionado de un inhibidor de EGFR, un inhibidor de KRAS, un inhibidor de KRAS-G12C, un inhibidor de MEK, un inhibidor de Bcl-2, un inhibidor de SOS1, un inhibidor de PARP, un inhibidor de RAF, un inhibidor de ERK, un inhibidor de CDK4/6, un inhibidor de MALT1, un inhibidor de BTK, un inhibidor de MAT2A, un inhibidor de PI3K, un inhibidor de AKT, un inhibidor de FGFR, un inhibidor de PRMT de tipo I, un agonista de STING o un inhibidor/modulador del punto de control inmunitario.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921042899 | 2019-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22032209A true ECSP22032209A (es) | 2022-05-31 |
Family
ID=73198360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202232209A ECSP22032209A (es) | 2019-10-22 | 2022-04-21 | Combinación farmacéutica de inhibidores de prmt5 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220395508A1 (es) |
EP (1) | EP4048270A1 (es) |
JP (1) | JP2023504230A (es) |
KR (1) | KR20220086628A (es) |
AU (1) | AU2020371295A1 (es) |
BR (1) | BR112022007808A2 (es) |
CA (1) | CA3156135A1 (es) |
CO (1) | CO2022005053A2 (es) |
CR (1) | CR20220175A (es) |
EC (1) | ECSP22032209A (es) |
IL (1) | IL292229A (es) |
MX (1) | MX2022004917A (es) |
PE (1) | PE20221154A1 (es) |
WO (1) | WO2021079302A1 (es) |
ZA (1) | ZA202203770B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022253455A1 (en) * | 2021-04-08 | 2023-11-02 | Mirati Therapeutics, Inc. | Combination therapies using prmt5 inhibitors for the treatment of cancer |
MX2023011853A (es) * | 2021-04-08 | 2023-12-07 | Mirati Therapeutics Inc | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer. |
WO2023001133A1 (zh) * | 2021-07-20 | 2023-01-26 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
AU2022316200A1 (en) * | 2021-07-20 | 2024-01-25 | Inspirna, Inc. | Compositions and methods for inhibiting creatine transport as a treatment for cancer |
WO2023131305A1 (zh) * | 2022-01-06 | 2023-07-13 | 江苏先声药业有限公司 | Prmt5抑制剂和抗癌治疗剂的组合 |
CN116655638B (zh) * | 2022-05-12 | 2024-01-26 | 上海齐鲁制药研究中心有限公司 | 氘代prmt5抑制剂 |
CN116211869B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 含dna损伤修复抑制剂的药物混合物及混合方法、用途 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
EP2935247B1 (en) | 2012-12-21 | 2019-08-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
CA2899363A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
JP6678455B2 (ja) | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
EP2935243B1 (en) | 2012-12-21 | 2018-03-14 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
CA2942833A1 (en) | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
EP3160477A4 (en) | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2952567A1 (en) | 2014-06-25 | 2015-12-30 | Glaxosmithkline Intellectual Property Development Limited | Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide |
EP3160466A4 (en) | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2953572A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US10005792B2 (en) | 2014-09-03 | 2018-06-26 | Ctxt Pty. Ltd. | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors |
GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
WO2016034673A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
WO2016038550A1 (en) | 2014-09-11 | 2016-03-17 | Novartis Ag | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
US10479997B2 (en) * | 2014-12-01 | 2019-11-19 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
WO2016145150A2 (en) | 2015-03-11 | 2016-09-15 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
TWI791251B (zh) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
EP3878850A1 (en) * | 2016-12-22 | 2021-09-15 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
EP3665179B1 (en) * | 2017-08-09 | 2021-06-09 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
EP3678703A1 (en) * | 2017-09-07 | 2020-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
GEP20227359B (en) | 2017-12-13 | 2022-03-10 | Lupin Ltd | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
-
2020
- 2020-10-22 IL IL292229A patent/IL292229A/en unknown
- 2020-10-22 KR KR1020227016800A patent/KR20220086628A/ko unknown
- 2020-10-22 PE PE2022000657A patent/PE20221154A1/es unknown
- 2020-10-22 EP EP20803923.0A patent/EP4048270A1/en active Pending
- 2020-10-22 JP JP2022524048A patent/JP2023504230A/ja active Pending
- 2020-10-22 CR CR20220175A patent/CR20220175A/es unknown
- 2020-10-22 AU AU2020371295A patent/AU2020371295A1/en active Pending
- 2020-10-22 BR BR112022007808A patent/BR112022007808A2/pt unknown
- 2020-10-22 MX MX2022004917A patent/MX2022004917A/es unknown
- 2020-10-22 CA CA3156135A patent/CA3156135A1/en active Pending
- 2020-10-22 WO PCT/IB2020/059921 patent/WO2021079302A1/en active Application Filing
- 2020-10-22 US US17/767,270 patent/US20220395508A1/en active Pending
-
2022
- 2022-04-01 ZA ZA2022/03770A patent/ZA202203770B/en unknown
- 2022-04-21 EC ECSENADI202232209A patent/ECSP22032209A/es unknown
- 2022-04-22 CO CONC2022/0005053A patent/CO2022005053A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
ZA202203770B (en) | 2022-12-21 |
KR20220086628A (ko) | 2022-06-23 |
CA3156135A1 (en) | 2021-04-29 |
IL292229A (en) | 2022-06-01 |
AU2020371295A1 (en) | 2022-04-28 |
WO2021079302A1 (en) | 2021-04-29 |
US20220395508A1 (en) | 2022-12-15 |
CO2022005053A2 (es) | 2022-04-29 |
MX2022004917A (es) | 2022-08-04 |
BR112022007808A2 (pt) | 2022-07-05 |
CR20220175A (es) | 2022-06-21 |
CN114599361A (zh) | 2022-06-07 |
EP4048270A1 (en) | 2022-08-31 |
PE20221154A1 (es) | 2022-07-18 |
JP2023504230A (ja) | 2023-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022005053A2 (es) | Combinación farmacéutica de inhibidores de prmt5 | |
CR20190252A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
CL2019000511A1 (es) | Inhibidores de procesos metabólicos celulares. | |
CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
BR112015023203A2 (pt) | métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos | |
EA201790398A1 (ru) | Способы лечения заболевания печени | |
MX2020003959A (es) | Metodos terapeuticos relacionados con los inhibidores de hsp90. | |
BR112015012295A8 (pt) | Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer | |
CO2019012473A2 (es) | Antagonistas del receptor de hidrocarburos de arilo y usos de los mismos | |
CO6531463A2 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
AR080872A1 (es) | Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad | |
PE20220562A1 (es) | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida | |
SG10201909199PA (en) | Method for treating cancer | |
BR112018074238A2 (pt) | combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
BR112018071600A2 (pt) | métodos, composições e usos relacionados aos mesmos | |
PA8578001A1 (es) | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas | |
CL2021002865A1 (es) | Composiciones farmacéuticas inyectables y sus usos. | |
BR112017018198A2 (pt) | inibição da atividade de olig2 | |
CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
CL2021003170A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
CL2023001637A1 (es) | Inhibidores de la vía jak1 para el tratamiento del vitíligo. | |
BR112018007358A2 (pt) | derivados de 1,4-dicarbonil-piperidila | |
BR112021006250A2 (pt) | método, e, método para rompimento seletivo de uma ou mais camadas de gordura subcutânea |